Melanoma Institute Australia welcomes new CEO Matthew Browne
9 August 2018
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Matthew, who takes up the position effective immediately, brings to the organisation a wealth of experience in managing organisations involved in health care and major infrastructure projects.
He has been with Melanoma Institute Australia since January 2017, having performed the roles of Chief Financial Officer and Company Secretary, and more recently Acting CEO. Prior to joining Melanoma Institute Australia, Matthew was Acting CEO for Cure Brain Cancer Foundation and held a variety of senior executive roles responsible for Transport NSW’s Opal smartcard ticketing project, including Director of Ticketing.
Matthew holds a Bachelor of Economics from Macquarie University and has been a member of the Institute of Chartered Accountants in Australia since 1990.
Chairman of Melanoma Institute Australia, Mr Grant King said; “We are excited to welcome Matthew as CEO of Melanoma Institute Australia as his leadership skills and experience in the medical research and not for profit sectors will ensure the organisation continues to be a world leader in melanoma prevention, treatment and cure.”
“Given Matthew’s previous executive roles, including at Melanoma Institute Australia, we are confident his transition into the CEO role will be smooth and effective and the organisation will continue its momentum towards its mission of zero deaths from melanoma,” he said.
“I am delighted and honoured to be leading such a world-class organisation,” Matthew Browne said. “I am proud of the achievements made by Melanoma Institute Australia over many years, providing patients with melanoma the very best standard of care and more life-saving treatment options.
“Melanoma Institute Australia is deeply committed to achieving its mission, and it will truly be a time to celebrate when that day arrives,” he said.
For more information, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | email@example.com
Sunscreen tips for a skin smart summer with the help of Professor Pascale Guitera, Dermatologist Associate for Melanoma Institute Australia.
Although survival rates for people with skin melanoma are increasing, these promises of hope are not being seen in uveal melanoma. Researchers are desperately trying to uncover new ways to treat this disease.
Lucinda Ryan and Carole Renouf talking about melanoma preventation and awareness on 720 ABC Perth.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.